Safety study of CC-97540 for anti-AQP4 antibody positive neuromyelitis optica
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study tests whether a new experimental medicine called CC-97540 is safe and well-tolerated in patients with a rare neurological disease called neuromyelitis optica spectrum disorder (NMOSD) who have a specific antibody marker (anti-AQP4). The trial involves a procedure that removes and reprocesses some of your immune cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Confirmed diagnosis of NMOSD with anti-AQP4 antibodies (detected by a specific blood test)
- Currently stable on either ravulizumab or satralizumab treatment for at least 6 months with no disease flare-ups in the last year
- Age 18–60 years old with relatively preserved eyesight (at least 20/200 in one eye) and mobility (EDSS score 6.5 or lower)
- No active infections, uncontrolled heart disease, or other serious conditions that could interfere with the study
- Up to date on meningococcal vaccines and able to undergo a leukapheresis procedure (a blood cell collection process) and MRI imaging
- Normal liver function tests and adequate peripheral B cells (>5% by flow cytometry)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This registry collects health and relapse information from adults with AQP4-positive NMOSD who are taking C5-blocking medicines to prevent long-term relapses. It helps researchers better understand treatment patterns and outcomes in real-world care.
This study tests if ravulizumab can lower certain nerve damage markers in people with AQP4-positive neuromyelitis optica. It may help understand how well the treatment works.
This trial is testing monoclonal antibody treatments for people with a specific type of neuromyelitis optica spectrum disorder (NMOSD) caused by AQP4 antibodies. It aims to see if these targeted therapies can help control the disease and prevent relapses.
This trial tests a new drug called IMC-002 for people with neuromyelitis optica spectrum disorder (NMOSD) who have a specific antibody (AQP4+). It aims to see if IMC-002 is safe and effective at preventing attacks.
This trial tests a new treatment called modified zipper therapy for people with neuromyelitis optica spectrum disorder (NMOSD) who have a specific antibody (AQP4-IgG) in their blood. It aims to stop a recent attack and improve recovery.
This trial compares several medications to see which works best for NMOSD, an autoimmune disease that can cause vision loss and paralysis. You must have a specific antibody (AQP4-IgG) to join.
Hear when a new AQP4+ NMOSD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.